CORONA Remedies Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- ✓Excellent return on equity (ROE 29.5%)
- ✓Efficient capital deployment (ROCE 33.3%)
- ✓Low debt relative to equity (D/E 0.2x)
Concerns
- ✗High premium to book value (P/B 17.1x)
- ✗Trading near 52-week high (₹2,124)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,944 | ₹4.6L Cr | 37.3 | 5.59 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹7,388 | ₹1.9L Cr | 73.4 | 11.71 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹5,040 | ₹1.6L Cr | 73.6 | 20.32 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,939 | ₹1.3L Cr | 64.9 | 13.56 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,416 | ₹1.1L Cr | 30.1 | 3.32 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,123 | ₹1.1L Cr | 21 | 4.17 | 21.2 | 21.1 | 0.38 |
| LUPIN Lupin Limited | ₹2,405 | ₹1.1L Cr | 19.6 | 4.9 | 28.7 | 29.9 | 0.32 |
Showing 7 peers in the same sector · Sorted by market cap
Corporate Events
To consider and approve the financial results for the period ended Jun 30, 2026
Dividend - Rs 10 Per Share
To consider and approve the financial results for the period ended March 31, 2026 and recommend final dividend, if any, on the equity shares of the Company for the financial year ended March 31, 2026.
Latest News
All news →CORONA Remedies to hold shareholder meeting on July 09, 2026
*CORONA Remedies to hold shareholder meeting on July 09, 2026.* The company has scheduled a meeting of shareholders for **July 09, 2026**, as per its NSE filing. Purpose of the meeting is not specified in the notice. Such meetings typically address routine corporate matters or resolutions. 📊 *STOCKS:* CORONAREMED | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ShareholderMeeting
Corona Remedies announces 22nd AGM and record date
*Corona Remedies announces 22nd AGM and record date.* The company has published notice of its 22nd Annual General Meeting with intimation of record date and e-voting details. Shareholders as of the record date will be eligible to vote. The announcement is part of routine corporate compliance. 📊 *STOCKS:* CORONAREMED | 🏢 *SECTOR:* Pharma | #LOWIMPACT #AGM
CORONA Remedies to host analyst and investor call.
*CORONA Remedies to host analyst and investor call.* The company has scheduled a conference call for analysts and institutional investors. This event is part of routine investor communication. No financial updates or major announcements were disclosed. 📊 *STOCKS:* CORONAREMEDY | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Earnings
Financials
Quarterly Results
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | ₹353 Cr ▲3.2% | ₹342 Cr ▼5.3% | ₹361 Cr ▲4.0% | ₹347 Cr ▲18.0% | ₹294 Cr ▼1.3% | ₹298 Cr ▼5.1% | ₹314 Cr |
| Op. Profit | ₹62 Cr ▼25.3% | ₹83 Cr ▲6.4% | ₹78 Cr ▲11.4% | ₹70 Cr ▲29.6% | ₹54 Cr ▼21.7% | ₹69 Cr ▲3.0% | ₹67 Cr |
| OPM | 18.0% ▼25.0% | 24.0% ▲9.1% | 22.0% ▲10.0% | 20.0% ▲11.1% | 18.0% ▼21.7% | 23.0% ▲9.5% | 21.0% |
| Net Profit | ₹45 Cr ▲9.8% | ₹41 Cr ▼21.2% | ₹52 Cr ▲13.0% | ₹46 Cr ▲43.8% | ₹32 Cr ▼28.9% | ₹45 Cr ▲4.7% | ₹43 Cr |
| EPS (₹) | 7.41 ▲9.8% | 6.75 ▼21.1% | 8.55 ▲13.2% | 7.55 ▲46.3% | 5.16 ▼29.8% | 7.35 ▲4.6% | 7.03 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | ₹1.4K Cr ▲17.3% | ₹1.2K Cr ▲17.9% | ₹1.0K Cr ▲14.7% | ₹884 Cr |
| Expenses | ₹1.1K Cr ▲16.0% | ₹956 Cr ▲11.3% | ₹859 Cr ▲13.6% | ₹756 Cr |
| Op. Profit | ₹294 Cr ▲22.0% | ₹241 Cr ▲54.5% | ₹156 Cr ▲21.9% | ₹128 Cr |
| OPM | 21.0% ▲5.0% | 20.0% ▲33.3% | 15.0% ▲7.1% | 14.0% |
| Other Income | ₹-9 Cr ▼250.0% | ₹6 Cr ▲20.0% | ₹5 Cr ▼28.6% | ₹7 Cr |
| Interest | ₹7 Cr ▼36.4% | ₹11 Cr ▼21.4% | ₹14 Cr ▲250.0% | ₹4 Cr |
| Depreciation | ₹38 Cr ▲2.7% | ₹37 Cr ▲32.1% | ₹28 Cr ▲40.0% | ₹20 Cr |
| PBT | ₹240 Cr ▲20.6% | ₹199 Cr ▲68.6% | ₹118 Cr ▲6.3% | ₹111 Cr |
| Tax % | 23.0% ▼8.0% | 25.0% ▲4.2% | 24.0% ▲4.3% | 23.0% |
| Net Profit | ₹185 Cr ▲24.2% | ₹149 Cr ▲65.6% | ₹90 Cr ▲5.9% | ₹85 Cr |
| EPS (₹) | 30.27 ▲23.9% | 24.43 ▲65.1% | 14.8 ▲6.6% | 13.89 |
| Div Payout | 33.0% ▲10.0% | 30.0% ▲20.0% | 25.0% ▲25.0% | 20.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|
| Liabilities | |||||
| Equity Capital | ₹61 Cr ▲0.0% | ₹61 Cr ▲0.0% | ₹61 Cr ▲0.0% | ₹61 Cr ▲0.0% | ₹61 Cr |
| Reserves | ₹686 Cr ▲14.7% | ₹598 Cr ▲9.7% | ₹545 Cr ▲30.1% | ₹419 Cr ▲20.7% | ₹347 Cr |
| Borrowings | ₹165 Cr ▲161.9% | ₹63 Cr ▼26.7% | ₹86 Cr ▼45.9% | ₹159 Cr ▲467.9% | ₹28 Cr |
| Other Liabilities | ₹293 Cr ▲15.4% | ₹254 Cr ▲7.2% | ₹237 Cr ▲24.1% | ₹191 Cr ▲20.1% | ₹159 Cr |
| Total Liabilities | ₹1.2K Cr ▲23.3% | ₹977 Cr ▲5.1% | ₹930 Cr ▲11.9% | ₹831 Cr ▲39.7% | ₹595 Cr |
| Assets | |||||
| Fixed Assets | ₹554 Cr ▲40.6% | ₹394 Cr ▲6.5% | ₹370 Cr ▼3.6% | ₹384 Cr ▲107.6% | ₹185 Cr |
| CWIP | ₹143 Cr ▼30.2% | ₹205 Cr ▲10.2% | ₹186 Cr ▲53.7% | ₹121 Cr ▲86.2% | ₹65 Cr |
| Investments | ₹26 Cr | ₹0 Cr ▼100.0% | ₹26 Cr ▲0.0% | ₹26 Cr ▼18.8% | ₹32 Cr |
| Other Assets | ₹482 Cr ▲27.5% | ₹378 Cr ▲8.6% | ₹348 Cr ▲15.6% | ₹301 Cr ▼4.1% | ₹314 Cr |
| Total Assets | ₹1.2K Cr ▲23.3% | ₹977 Cr ▲5.1% | ₹930 Cr ▲11.9% | ₹831 Cr ▲39.7% | ₹595 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Operating CF | ₹229 Cr ▲20.5% | ₹190 Cr ▲21.0% | ₹157 Cr ▲52.4% | ₹103 Cr |
| Investing CF | ₹-256 Cr ▼204.8% | ₹-84 Cr ▲68.5% | ₹-267 Cr ▼434.0% | ₹-50 Cr |
| Financing CF | ₹25 Cr ▲123.4% | ₹-107 Cr ▼208.1% | ₹99 Cr ▲320.0% | ₹-45 Cr |
| Net Cash Flow | ₹-1 Cr | ₹0 Cr ▲100.0% | ₹-11 Cr ▼237.5% | ₹8 Cr |
| Free Cash Flow | ₹56 Cr ▼43.4% | ₹99 Cr ▲176.7% | ₹-129 Cr ▼1533.3% | ₹9 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Debtor Days | 38d ▲5.6% | 36d ▲0.0% | 36d ▲0.0% | 36d |
| Inventory Days | 175d ▼12.5% | 200d ▲26.6% | 158d ▼13.2% | 182d |
| Days Payable | 206d ▼6.8% | 221d ▲20.1% | 184d ▲12.9% | 163d |
| Cash Conv. Cycle | 7d ▼50.0% | 14d ▲40.0% | 10d ▼81.8% | 55d |
| Working Capital Days | -15d ▼266.7% | 9d ▲550.0% | -2d ▼106.7% | 30d |
| ROCE | 33.0% ▲3.1% | 32.0% ▲28.0% | 25.0% | — |
Source: Screener.in · Lower days = better efficiency
About CORONA Remedies Limited
Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas.[1]
Healthcare · Pharmaceuticals & Biotechnology